var data={"title":"Isotretinoin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Isotretinoin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6412?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">see &quot;Isotretinoin: Drug information&quot;</a> and <a href=\"topic.htm?path=isotretinoin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Isotretinoin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708957\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Isotretinoin must not be used by women and adolescents who are pregnant or who may become pregnant. There is an extremely high risk that severe birth defects can result if pregnancy occurs while taking isotretinoin in any amount, even for short periods of time. Potentially, any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Birth defects that have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, CNS, cardiovascular system, and thymus and parathyroid glands. Cases of intelligence quotient (IQ) scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Documented external abnormalities include skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases, death has occurred with some of the abnormalities previously noted.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If pregnancy does occur during treatment of a female patient who is taking isotretinoin, isotretinoin must be discontinued immediately and she should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for further evaluation and counseling.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Special prescribing requirements:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of isotretinoin's teratogenicity and to minimize fetal exposure, isotretinoin is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This program is called iPLEDGE. Isotretinoin must only be prescribed by prescribers who are registered and activated with the iPLEDGE program. Isotretinoin must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are registered and meet all the requirements of iPLEDGE.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185177\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Absorica;</li>\n      <li>Amnesteem;</li>\n      <li>Claravis;</li>\n      <li>Myorisan;</li>\n      <li>Zenatane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185178\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Accutane;</li>\n      <li>Clarus;</li>\n      <li>Epuris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048091\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Acne Products</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Retinoic Acid Derivatives</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Retinoic Acid Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin A Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048084\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">see &quot;Isotretinoin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne vulgaris, severe recalcitrant nodular:</b> Children &ge;12 years and Adolescents: Oral: 0.5 to 1 mg/kg/day in 2 divided doses; for severe cases (involving trunk, nuchal region, lower back, buttocks, thighs) may require higher doses up to 2 mg/kg/day in 2 divided doses. Duration of therapy is typically 15 to 20 weeks or until the total cyst count decreases by 70%, whichever is sooner; an alternate reported approach is continuation until a total cumulative dose of 120 mg/kg (eg, 1 mg/kg/day for 120 days). An initial dose of &le;0.5 mg/kg/day may be used to minimize initial flaring (Strauss 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne vulgaris, moderate:</b> Limited data available: Children &ge;12 years and Adolescents: 20 mg/day (~0.3 to 0.5 mg/kg/day) continued for 6 to 12 months to cumulative dose 120 mg/kg has been shown effective (Amichai 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma, maintenance:</b> Infants, Children, and Adolescents: Oral: 80 mg/m<sup>2</sup>/dose every 12 hours for the last 2 weeks (14 consecutive days) of a 4-week cycle for 6 cycles; dinutuximab therapy is administered during the first week of the 4-week cycle (Yu 2010); begin after continuation chemotherapy or transplantation (Matthay 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Acne vulgaris:</b> Oral: 0.5 to 1 mg/kg/day in 2 divided doses for 15 to 20 weeks or until the total cyst count decreases by 70%, whichever is sooner. Adults with very severe disease/scarring or primarily involves the trunk may require dosage adjustment up to 2 mg/kg/day. A second course of therapy may be initiated after a period of &ge;2 months of therapy. An initial dose of &le;0.5 mg/kg/day may be used to minimize initial flaring (Strauss 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment prior to treatment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatotoxicity during treatment: Liver enzymes may normalize with dosage reduction or with continued treatment; discontinue if normalization does not readily occur or if hepatitis is suspected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185155\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorica: 10 mg, 20 mg [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorica: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow), soybean oil, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorica: 30 mg [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorica: 35 mg [contains fd&amp;c blue #2 (indigotine), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorica: 40 mg [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amnesteem: 10 mg, 20 mg, 40 mg [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claravis: 10 mg [contains fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claravis: 20 mg [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claravis: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claravis: 40 mg [contains fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myorisan: 10 mg, 20 mg [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myorisan: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myorisan: 40 mg [contains fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenatane: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1), edetate disodium, fd&amp;c yellow #10 (quinoline yellow), methylparaben, propylparaben, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenatane: 20 mg [contains edetate disodium, methylparaben, propylparaben, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenatane: 30 mg [contains edetate disodium, fd&amp;c blue #2 aluminum lake, fd&amp;c yellow #10 (quinoline yellow), methylparaben, propylparaben, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenatane: 40 mg [contains brilliant blue fcf (fd&amp;c blue #1), edetate disodium, fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow), methylparaben, propylparaben, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185139\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874644\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Absorica: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM306859.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5Ws+woYOysG19E6G4kKCKJCg==&amp;TOPIC_ID=13395\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM306859.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Accutane: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085812.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlpmQw7TFC2h43xZtA/r8olw==&amp;TOPIC_ID=13395\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085812.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Sotret: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089135.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlJPSy5oC8ghEfvT01puodPg==&amp;TOPIC_ID=13395\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089135.pdf`</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048095\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Oral: Administer orally with a meal (except Absorica, which may be taken without regard to meals). According to the manufacturers&rsquo; labeling, capsules should be swallowed whole with a full glass of liquid. For patients unable to swallow capsule whole, an oral liquid may be prepared; may irritate esophagus if contents are removed from the capsule. In pediatric neuroblastoma trial when patient was unable to swallow capsule, the end of capsule was punctured/cut and capsules contents extruded into ice cream or yogurt (high-fat food); if capsule is opened, contents must be consumed immediately to avoid degradation of the drug (Matthay 1999; Veal 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132640\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185172\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg; F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048094\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of severe recalcitrant nodular acne unresponsive to conventional therapy, including systemic antibiotics (FDA approved in ages &ge;12 years and adults); has also been used  for the treatment of moderate acne and high-risk neuroblastoma </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185227\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Accutane may be confused with Accolate, Accupril</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Claravis may be confused with Cleviprex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ISOtretinoin may be confused with tretinoin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Isotretinoin may be confused with tretinoin (which is also called all-<i>trans</i> retinoic acid, or ATRA); while both products may have uses in cancer treatment, they are <b>not</b> interchangeable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185224\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cerebrovascular accident, chest pain, edema, flushing, palpitations, syncope, tachycardia, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aggressive behavior, attempted suicide, depression, dizziness, drowsiness, emotional lability, fatigue, headache, insomnia, lethargy, malaise, nervousness, paresthesia, pseudotumor cerebri, psychosis, seizure, suicidal ideation, vasculitis (renal), violent behavior</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne fulminans, allergic skin reaction, alopecia, cheilitis, diaphoresis, eczema, eruptive xanthoma, facial erythema, hair disease, hirsutism, hyperpigmentation, hypopigmentation, nail disease, paronychia, pruritus, pyogenic granuloma, scaling of skin of feet, skin atrophy, skin photosensitivity, skin rash, sunburn (increased susceptibility), superficial peeling of palms, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased HDL cholesterol, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum cholesterol, increased serum glucose, increased serum triglycerides, hyperuricemia, menstrual disease, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Colitis, esophagitis, esophageal ulcer, gastrointestinal symptoms (nonspecific), gingival hemorrhage, gingivitis, inflammatory bowel disease, nausea, pancreatitis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Genitourinary disease (nonspecific findings), hematuria, proteinuria, pyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bruise, lymphadenopathy, neutropenia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes simplex infection (disseminated), infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain (children), bone disease, calcification of ligament, calcification of tendon, decreased bone mineral density, increased creatine phosphokinase, myalgia, premature epiphyseal closure, skeletal hyperostosis, tendonitis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharitis, cataract, chalazion, conjunctivitis, corneal opacity, hordeolum, keratitis, nocturnal amblyopia, optic neuritis, photophobia, vision color changes, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory impairment, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Glomerulonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dry nose, epistaxis, respiratory tract infection, voice disorder, Wegener's granulomatosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, contact lens intolerance, decreased visual acuity, dry eye syndrome, erythema multiforme, eye pain, eyelid disease (meibomian gland dysfunction/atrophy; Neudorfer 2012), myopia, rhabdomyolysis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185160\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to isotretinoin or any component of the formulation; sensitivity to parabens (Zenatane only) or vitamin A; pregnant women or those who may become pregnant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications not in the US labeling: Breastfeeding, hepatic or renal insufficiency, hypervitaminosis A, excessive hyperlipidemia, concurrent tetracycline therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for retinoids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185143\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Auditory impairment: Hearing impairment, which can continue after therapy is discontinued, may occur. Discontinue therapy if hearing impairment or tinnitus develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density loss: May decrease bone mineral density; osteoporosis, osteopenia, bone fractures, and delayed healing of bone fractures have been reported. Use caution in patients with a genetic predisposition for bone loss (eg, age-related osteoporosis, history of childhood osteoporosis  conditions, osteomalacia or other disorders of bone metabolism); including patients diagnosed with anorexia nervosa and those on concomitant medications that may cause drug-induced osteoporosis/osteomalacia and/or affect vitamin D metabolism (eg, systemic corticosteroids, anticonvulsants). Patients may be at increased risk when participating in activities with repetitive impact (such as sports) where the risk of spondylolisthesis with and without pars fractures and hip growth plate injuries in early and late adolescence are known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Postmarketing reports of erythema multiforme severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), including fatalities, have been reported; monitor for severe skin reactions; discontinue use if severe skin reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Growth effects: Skeletal hyperostosis and premature epiphyseal closure have also been reported with the use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Neutropenia and rare cases of agranulocytosis have been reported; discontinue if clinically significant decreases in white cell counts occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Clinical hepatitis and mild to moderate elevated liver enzymes have been reported with use; liver enzymes may normalize with dosage reduction or with continued treatment. Discontinue therapy if hepatic enzymes do not normalize or if hepatitis is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylaxis and other types of allergic reactions, including cutaneous reactions and serious cases of allergic vasculitis, often with purpura of the extremities and extracutaneous involvement (including renal) have been reported. Discontinue therapy if a serious allergic reaction occurs and institute appropriate medical management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inflammatory bowel disease: Inflammatory bowel disease, including regional ileitis, has been reported in patients without a prior history of intestinal disorders; discontinue treatment immediately if abdominal pain, rectal bleeding, or severe diarrhea occurs. Of note, a position statement from the American Academy of Dermatology states that based on currently available data, there is insufficient evidence to prove either an association or a causal relationship between IBD and isotretinoin use (AAD 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Musculoskeletal effects: Musculoskeletal symptoms (including arthralgia) have been reported; generally symptoms were mild to moderate, but occasionally required discontinuation of therapy. Transient pain in the chest has occurred; symptoms generally cleared after discontinuation of therapy, but in some cases persisted. Rhabdomyolysis, some associated with strenuous physical activity, has been reported (rarely).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Vision impairment, corneal opacities, decreased tolerance to contact lenses (due to dry eyes), and decreased night vision have been reported with use; discontinue therapy in patients experiencing visual difficulties. Warn patients to be cautious when driving or operating machinery at night.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Acute pancreatitis may occur in patients with normal or elevated triglyceride levels; fatal hemorrhagic pancreatitis (rare) has been reported; discontinue therapy if hypertriglyceridemia cannot be controlled at an acceptable level or symptoms of pancreatitis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Avoid prolonged exposure to UV rays or sunlight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pseudotumor cerebri: Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting, and visual disturbances; discontinue immediately and refer patient to a neurologist if papilledema occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric effects: May cause depression, psychosis, mood disturbance, and rarely, suicidal ideation, suicide attempts, suicide, and aggressive and/or violent behaviors. All patients should be observed closely for symptoms of depression or suicidal thoughts. Discontinue therapy if depression, mood disturbance, psychosis, or aggression develops. Discontinuation of treatment alone may not be sufficient, further evaluation may be necessary. Use with extreme caution in patients with a history of psychiatric disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; impaired glucose control has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Marked elevations of serum triglycerides have been reported; use with caution in patients with hypertriglyceridemia or those who may be at high risk (eg, patients with diabetes, obesity, increased alcohol intake, family history of or those with lipid metabolism disorder). The effects on triglycerides, HDL, and cholesterol have been  reversible upon discontinuation of therapy. Instruct patients to avoid or limit ethanol; may increase triglyceride levels if taken in excess.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warnings]: Use of isotretinoin is contraindicated in females who are or may become pregnant. Birth defects (facial, eye, ear, skull, central nervous system, cardiovascular, thymus and parathyroid gland abnormalities) have been noted following isotretinoin exposure during pregnancy and the risk for severe birth defects is high, with any dose or even with short treatment duration. Low IQ scores have also been reported. The risk for spontaneous abortion and premature births is increased. Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE risk evaluation and mitigation strategy (REMS) program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug. If pregnancy occurs during therapy, isotretinoin should be discontinued immediately and the patient referred to an obstetrician-gynecologist specializing in reproductive toxicity.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Absorica: Absorption is ~83% greater than Accutane when administered under fasting conditions; they are bioequivalent when taken with a high-fat meal. Absorica is <b>not</b> interchangeable with other generic isotretinoin products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchange: Isotretinoin and tretinoin (which is also known as all-<i>trans</i> retinoic acid, or ATRA) may be confused, while both products may be used in cancer treatment, they are <b>not</b> interchangeable; verify product prior to dispensing and administration to prevent medication errors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some products may contain tartrazine (FD&amp;C yellow no. 5), which may cause allergic reactions, including bronchial asthma, in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood donation: Patients should be instructed not to donate blood during therapy and for 1 month following discontinuation of therapy due to risk of donated blood being given to a pregnant female.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced health care provider: This medication should only be prescribed by health care providers competent in treating severe recalcitrant nodular acne and experienced with the use of systemic retinoids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: Safety of long-term use is not established and is not recommended; the effect on bone loss is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: <b>[US Boxed Warning]: Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE risk evaluation and mitigation strategy (REMS) management program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug</b> (see Additional Information or Pharmacotherapy Pearls for details). Women of childbearing potential must be capable of complying with effective contraceptive measures. Patients must select and commit to two forms of contraception. Therapy is begun after two negative pregnancy tests; effective contraception must be used for at least 1 month before beginning therapy, during therapy, and for 1 month after discontinuation of therapy. Prescriptions should be written for no more than a 30-day supply, and pregnancy testing and counseling should be repeated monthly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin resurfacing procedures: Avoid skin resurfacing procedures (eg, dermabrasion, laser) and wax epilation during therapy and for at least 6 months after discontinuation of isotretinoin due to the risk of scarring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023253\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Children may experience a higher frequency of some adverse effects including arthralgia (22%) and back pain (29%). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299550\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185148\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13395&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of ISOtretinoin. Specifically, the risk for elevated triglyceride concentrations may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: ISOtretinoin may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185173\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Isotretinoin bioavailability increased if taken with food or milk. Management: Administer orally with a meal (except Absorica which may be taken without regard to meals). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185150\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185163\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Isotretinoin and its metabolites can be detected in fetal tissue following maternal use during pregnancy (Benifla 1995; Kraft 1989). <b>[US Boxed Warnings]: Use of isotretinoin is contraindicated in females who are or may become pregnant. Birth defects (facial, eye, ear, skull, central nervous system, cardiovascular, thymus and parathyroid gland abnormalities) have been noted following isotretinoin exposure during pregnancy and the risk for severe birth defects is high, with any dose or even with short treatment duration. Low IQ scores have also been reported. The risk for spontaneous abortion and premature births is increased. Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk evaluation and mitigation strategy (REMS) program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug. If pregnancy occurs during therapy, isotretinoin should be discontinued immediately and the patient referred to an obstetrician-gynecologist specializing in reproductive toxicity. </b> This medication is contraindicated in females of childbearing potential unless they are able to comply with the guidelines of the iPLEDGE&trade; pregnancy prevention program. Females of childbearing potential must have two negative pregnancy tests with a sensitivity of at least 25 milliunits/mL prior to beginning therapy and testing should continue monthly during therapy. Females of childbearing potential should not become pregnant during therapy or for 1 month following discontinuation of isotretinoin. Upon discontinuation of treatment, females of childbearing potential should have a pregnancy test after their last dose and again one month after their last dose. Two forms of contraception should be continued during this time. Any pregnancies should be reported to the iPLEDGE&trade; program (www.ipledgeprogram.com or 866-495-0654) and the FDA through MedWatch (800-FDA-1088). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048090\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, baseline sedimentation rate, glucose, CPK; signs of depression, mood alteration, psychosis, aggression, severe skin reactions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregnancy test (for all female patients of childbearing potential): Two negative tests with a sensitivity of at least 25 mIU/mL prior to beginning therapy (the second performed at least 19 days after the first test and performed during the first 5 days of the menstrual period immediately preceding the start of therapy); monthly tests to rule out pregnancy prior to refilling prescription</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipids: Prior to treatment and at weekly or biweekly intervals until response to treatment is established. Test should not be performed &lt;36 hours after consumption of ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liver function tests: Prior to treatment and at weekly or biweekly intervals until response to treatment is established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185142\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reduces sebaceous gland size and reduces sebum production in acne treatment; in neuroblastoma, decreases cell proliferation and induces differentiation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185159\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Pharmacokinetic parameters in adolescents (12 to 15 years) are similar to adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Enhanced with a high-fat meal; Absorica absorption is ~83% greater than Accutane when administered under fasting conditions; they are bioequivalent when taken with a high-fat meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99% to 100%; primarily albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2B6, 2C8, 2C9, 3A4; forms metabolites; major metabolite: 4-oxo-isotretinoin (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: Parent drug: 21 hours; Metabolite: 21 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine and feces (equal amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5935063\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">For patients unable to swallow the capsules whole, an oral liquid may be prepared with softgel capsules (not recommended by the manufacturers) by one of the following methods:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Place capsules (softgel formulations only) in small container and add warm (~37&deg;C [97&deg;F]) water or milk to cover capsule(s); wait 2 to 3 minutes until capsule is softened and then drink the milk or water with the softened capsule, or swallow softened capsule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Puncture capsule (softgel formulations only) with needle or cut with scissors; squeeze capsule contents into 5 to 10 mL of milk or tube feed formula; draw mixture up into oral syringe and administer via feeding tube; flush feeding tube with &ge;30 mL additional milk or tube feeding formula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Puncture capsule (softgel formulations only) with needle or cut with scissors and draw contents into oral syringe; add 1 to 5 mL of medium chain triglyceride, soybean, or safflower oil to the oral syringe; mix gently and administer via feeding tube; flush feeding tube with &ge;30 mL milk or tube feeding formula.</p>\n    <div class=\"reference\">Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy.</i> 2011;31(2):164-192.<span class=\"pubmed-id\">21275495</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323242\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Absorica Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $405.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (10): $405.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (10): $435.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $435.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (10): $435.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (10): $435.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Amnesteem Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $180.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (10): $213.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (10): $248.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Claravis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $615.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $729.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $616.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $847.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (ISOtretinoin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $205.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (10): $243.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $205.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (10): $282.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Myorisan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $540.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $641.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $370.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $744.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zenatane Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $180.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (10): $213.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $744.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (10): $248.29</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185165\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Accotin (DK);</li>\n      <li>Acnal SC (KR);</li>\n      <li>Acnecur (PY);</li>\n      <li>Acnemin (ES);</li>\n      <li>Acnetrex (LK, PH);</li>\n      <li>Acnotin (CL, EC, HK, PE, SG, TH, VN);</li>\n      <li>Acnova (BR);</li>\n      <li>Acugen (PH);</li>\n      <li>Akinol (KR);</li>\n      <li>Aknenormin (DE);</li>\n      <li>Aknetin (UA);</li>\n      <li>Aknil Gel (BD);</li>\n      <li>Atlacne (AR);</li>\n      <li>Atretin (CO);</li>\n      <li>Ciscutan (AT);</li>\n      <li>Claravis (BM);</li>\n      <li>Contracne (FR);</li>\n      <li>Cosmin (PK);</li>\n      <li>Curacne (AE, JO, KW, LB, QA);</li>\n      <li>Curacne Ge (FR);</li>\n      <li>Curakne (CH);</li>\n      <li>Curatane (IL);</li>\n      <li>Dercutane (ES);</li>\n      <li>Dermatane (AU);</li>\n      <li>Hyndriax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Isocutan (AR);</li>\n      <li>Isoface (CO, CR, DO, EC, GT, HN, MX, NI, PA, PE, PY, SV, VE);</li>\n      <li>Isolve (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Isosupra (BE);</li>\n      <li>Isotane (NZ, TH);</li>\n      <li>Isotina (KR);</li>\n      <li>Isotinon (KR);</li>\n      <li>Isotren (KR);</li>\n      <li>Isotret-Hexal (DE);</li>\n      <li>Isotrex (AE, BH, BR, CL, CY, DK, GB, HU, ID, IE, LU, MX, PK, QA, SA, SG, TW);</li>\n      <li>Isotrex Gel (DE, ES, FR, HK, IL, IT, MY, PH, PL, TH);</li>\n      <li>Isotroin (IN, LB);</li>\n      <li>LOAC SC (KR);</li>\n      <li>Neotrex (MX);</li>\n      <li>Nimegen (MY, SG);</li>\n      <li>Oratane (AE, AU, MY, NZ, SG);</li>\n      <li>Procuta Ge (FR);</li>\n      <li>Reducar (HK);</li>\n      <li>Reticap-5 (BD);</li>\n      <li>Retigel (BD);</li>\n      <li>Roaccutan (AR, CO, EG, FI, HU, IT, MX, PE, PT, PY, UY, VE);</li>\n      <li>Roaccutane (AE, AU, BB, BE, BG, BH, BS, BZ, CH, CU, CY, CZ, EE, FR, GB, GH, GR, GY, HK, HR, IE, IL, IQ, IR, JM, JO, KE, KR, KW, LB, LK, LT, LU, LV, LY, NL, OM, PH, PK, PR, QA, SA, SI, SK, SR, SY, TH, TR, TT, TW, TZ, UG, YE, ZM);</li>\n      <li>Roacnetan (CN);</li>\n      <li>Roacta (TH);</li>\n      <li>Roacutan (BR);</li>\n      <li>Roakkutan (UA);</li>\n      <li>Rocta (AU);</li>\n      <li>Sotret (IN, TH);</li>\n      <li>Sotrexe (MX);</li>\n      <li>Tretinex (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Dermatology (AAD) website. Position statement on isotretinoin. https://www.aad.org/Forms/Policies/Uploads/PS/PS-Isotretinoin.pdf. Accessed August 1, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amichai B, Shemer A, and Grunwald MH, &quot;Low-Dose Isotretinoin in the Treatment of Acne Vulgaris,&quot; <i>J Am Acad Dermatol</i>, 2006, 54(4):644-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/16546586/pubmed\" target=\"_blank\" id=\"16546586\">16546586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benifla JL, Ville Y, Imbert MC, et al. Fetal tissue dosages of retinoids. Experimental study concerning a case of isotretinoin (Roaccutan) administration and pregnancy. Fetal Diagn Ther. 199510(3):189-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/7639942/pubmed\" target=\"_blank\" id=\"7639942\">7639942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brecher AR and Orlow SJ, &quot;Oral Retinoid Therapy for Dermatologic Conditions in Children and Adolescents,&quot; <i>J Am Acad Dermatol</i>, 2003, 49(2):171-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12894062/pubmed\" target=\"_blank\" id=\"12894062\">12894062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiGiovanna JJ and Peck GL, &ldquo;Oral Synthetic Retinoid Treatment in Children,&rdquo; <i>Pediatr Dermatol</i>, 1983, 1(1):77-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/ 6238291 /pubmed\" target=\"_blank\" id=\" 6238291 \"> 6238291 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft JC, Nau H, Lammer E, et al. Embryonic retinoid concentrations after maternal intake of isotretinoin. <i>N Engl J Med</i>. 1989;321(4):262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2747765/pubmed\" target=\"_blank\" id=\"2747765\">2747765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen GK. Iatrogenic breast discharge with isotretinoin. <i>Arch Dermatol</i>. 1985;121(4):450-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/3856419/pubmed\" target=\"_blank\" id=\"3856419\">3856419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matthay KK, Villablanca JG, Seeger RC, et al, &ldquo;Treatment of High-Risk Neuroblastoma With Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. Children's Cancer Group,&rdquo; <i>N Engl J Med,</i> 1999, 341:1165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/10519894/pubmed\" target=\"_blank\" id=\"10519894\">10519894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds CP, Kane DJ, Einhorn PA, et al, &ldquo;Response of Neuroblastoma to Retinoic Acid <i>In Vitro</i>, and <i>In Vivo</i>,&rdquo; <i>Prog Clin Biol Res</i>, 1991, 366:203-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2068138/pubmed\" target=\"_blank\" id=\"2068138\">2068138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strauss JS, Krowchuk DP, Leyden JJ, et al, &quot;Guidelines of Care for Acne Vulgaris Management,&quot; <i>J Am Acad Dermatol</i>, 2007, 56(4):651-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/17276540/pubmed\" target=\"_blank\" id=\"17276540\">17276540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veal GJ, Cole M, Errington J, et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. <i>Br J Cancer</i>. 2007;96(3):424-431.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/17224928/pubmed\" target=\"_blank\" id=\"17224928\">17224928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>N Engl J Med</i>. 2010;363(14):1324-1334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/20879881/pubmed\" target=\"_blank\" id=\"20879881\">20879881</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13395 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708957\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F185177\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F185178\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048091\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048084\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F185155\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F185139\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874644\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048095\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132640\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F185172\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048094\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F185227\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F185224\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F185160\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F185143\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023253\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299550\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F185148\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F185173\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F185150\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F185163\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048090\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F185142\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F185159\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F5935063\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323242\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F185165\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13395|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin: Drug information</a></li><li><a href=\"topic.htm?path=isotretinoin-patient-drug-information\" class=\"drug drug_patient\">Isotretinoin: Patient drug information</a></li></ul></div></div>","javascript":null}